Scalper1 News
Many biotechs and chips that got hammered Wednesday are already well extended past buy points. While they could set up a secondary buy opportunity, other leaders in early-stage bases may have the potential for a fresh breakout. These stocks have a Composite Rating of 90 or higher, belong to the top 20 industry groups tracked by IBD, and are in a first- or second-stage base. In short, the best of the best. This isn’t a buy list but fodder for Scalper1 News
Scalper1 News